首页> 外文期刊>Molecular pharmacology. >cAMP-Dependent Protein Kinase A (PKA)-Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes
【24h】

cAMP-Dependent Protein Kinase A (PKA)-Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes

机译:cAMP依赖性蛋白激酶A(PKA)介导的c-Myc降解取决于PKA-I和PKA-II同工酶的相对比例

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The transcription factor c-Myc regulates numerous target genes that are important for multiple cellular processes such as cell growth and differentiation. It is commonly deregulated in leukemia. Acute promyelocytic leukemia (APL) is characterized by a blockade of granulocytic differentiation at the promyelocyte stage. Despite the great success of all-trans retinoic acid (ATRA)-based therapy, which results in a clinical remission by inducing promyelocyte maturation, a significant number of patients relapse due to the development of ATRA resistance. A significant role has been ascribed to the cAMP/cAMP-dependent protein kinase A (PKA) signaling pathway in retinoid treatment since PKA activation is able to restore differentiation in some ATRA-resistant cells and eradicate leukemia-initiating cells in vivo. In this study, using NB4 APL cell variants resistant to ATRA-induced differentiation, we reveal distinct functional roles of the two PKA isozymes, PKA type I (PKA-I) and PKA-type II (PKA-II), on the steady-state level of c-Myc protein, providing a likely mechanism by which cAMP-elevating agents can restore differentiation in ATRA maturation-resistant APL cells. Therefore, both the inhibition of c-Myc activity and the PKA-I/PKA-II ratio should be taken into account if cAMP-based therapy is considered in the clinical management of APL.
机译:转录因子c-Myc调节许多靶基因,这些靶基因对于多种细胞过程(例如细胞生长和分化)很重要。它在白血病中通常被解除管制。急性早幼粒细胞白血病(APL)的特征是在早幼粒细胞阶段阻断了粒细胞分化。尽管基于全反式视黄酸(ATRA)的疗法取得了巨大成功,该疗法通过诱导早幼粒细胞成熟而导致临床缓解,但是由于ATRA耐药性的发展,仍有大量患者复发。在维甲酸治疗中,cAMP / cAMP依赖性蛋白激酶A(PKA)信号传导途径具有重要作用,因为PKA激活能够恢复某些ATRA耐药细胞的分化并在体内根除白血病起始细胞。在这项研究中,使用对ATRA诱导的分化具有抗性的NB4 APL细胞变体,我们发现了两种PKA同工酶(PKA I型(PKA-I)和PKA II型(PKA-II))在稳定状态下的独特功能。状态的c-Myc蛋白水平,提供了一种可能的机制,cAMP增强剂可通过这种机制恢复抗ATRA成熟的APL细胞的分化。因此,如果在APL的临床管理中考虑基于cAMP的治疗,则应同时考虑c-Myc活性的抑制和PKA-I / PKA-II的比率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号